BioCrysts

BioCrysts is a biotechnology company that specializes in the development and commercialization of crystalline protein-based therapeutics. The company's technology platform involves the production of highly pure, crystalline proteins that are designed to mimic the structure and function of native proteins found in the human body. These crystalline proteins are intended to be used as therapeutic agents to treat various diseases, including cancer, infectious diseases, and genetic disorders.

The company's approach to protein production involves the use of a proprietary crystallization process that allows for the production of large quantities of highly pure, crystalline proteins. This process involves the expression of the target protein in a host organism, followed by the purification and crystallization of the protein. The resulting crystalline proteins are then formulated into therapeutic agents that can be administered to patients.

BioCrysts has developed a pipeline of therapeutic candidates that are in various stages of clinical development. The company's lead product candidate, BC-100, is a crystalline protein-based therapeutic that is being developed for the treatment of cancer. BC-100 is designed to target and kill cancer cells by inducing apoptosis, a process of programmed cell death. The company has also developed other therapeutic candidates that are being evaluated for the treatment of infectious diseases and genetic disorders.

BioCrysts is headquartered in San Diego, California, and was founded in 2005. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol BCYC. As of 2021, BioCrysts has raised over $100 million in funding from various investors, including venture capital firms and strategic partners. The company's management team includes experienced professionals in the fields of biotechnology, pharmaceuticals, and business development.